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INTRODUCTION
Chronic graft-versus-host disease (GVHD) is the major
late complication of allogeneic bone marrow transplantation
(BMT) and has a signiﬁcant impact on quality of life [1] and
mortality [2]. The 3-year risk of nonrelapse mortality is 28%
for limited and 48% for extensive chronic GVHD [2]. The
incidence of chronic GVHD is increased in patients receiv-
ing alternative-donor grafts, both unrelated donor (UD) and
related mismatched donor, compared to the incidence in
patients receiving transplants from HLA-identical siblings
[3-5]. In severe cases of chronic GVHD, patients may
develop extensive scleroderma, crippling contractures, and
severe infections, with a mortality rate of up to 80% [5-7]. Lit-
tle progress has been made in the treatment of chronic
GVHD over the past 3 decades, with average mortality
remaining stable at 24% [8], and intensiﬁed immunosuppres-
sion does not seem to improve survival [9].
Several programs have been developed to prevent
GVHD: depletion of donor T-cells from the stem cell har-
vest [10], called ex vivo T-cell depletion; aggressive
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ABSTRACT
We studied the impact of preparative regimens with or without antithymocyte globulin (ATG) on chronic GVHD in
160 patients undergoing marrow transplants from unrelated donors (n = 127) or partially mismatched related donors
(n = 33). A conditioning regimen that included rabbit ATG, 7.5 to 15 mg/kg (Thymoglobuline; Sangstat, Lyon,
France), was given to 102 patients, whereas a conditioning regimen without ATG was given to 58 patients. The
median patient age was 34 years for the ATG group and 29 years for the non-ATG group (P = .002); otherwise the 2
groups were matched for disease phase, diagnosis, donor age, interval from diagnosis to transplantation, and number
of cells infused at the time of transplant. Median follow-up for surviving patients was 4.5 years (range, 1.5-9 years).
The conditioning regimen was cyclophosphamide (CY) and total body irradiation (TBI) in 95 patients and CY-
thiotepa in 65 patients; the source of stem cells was bone marrow for all patients. Acute GVHD grades II-IV and
grades III-IV were reduced in patients receiving ATG compared to patients not receiving ATG (51% versus 74%, P =
.004 and 14% versus 28%, P = .03, respectively). There were significantly fewer patients with chronic GVHD in the
ATG group than in the non-ATG group at 6 months (14% versus 30%, P = .03), 1 year (7% versus 41%, P = .0001), 2
years (16% versus 36%, P = .02), and 4 years (5% versus 34%, P = .002) and beyond 4 years (0% in 19 patients at risk
versus 29% in 24 patients at risk, P = .01). More patients in the ATG group than in the non-ATG group had a perfor-
mance status (Karnowski score) greater than 90 at last follow-up (93% versus 56%, P = .01) and had discontinued
cyclosporin treatment 2 years posttransplant (28% versus 3%, P = .003). Survival rates were comparable in the ATG
and non-ATG groups for patients who received TBI (56% versus 59%, P = .7) and those who received thiotepa (33%
versus 18%, P = .3). Transplant mortality and relapse rates were also comparable in the 2 groups for these patients. We
conclude that pretransplant ATG administration reduces the risk of acute and chronic GVHD, improves quality of life,
and increases the likelihood that discontinuation of immunosuppressive therapy will be possible.
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immunosuppression pretransplant, referred to as in vivo
T-cell depletion [11]; and combined immunosuppressive
therapy posttransplant [12]. For the latter, the preferred
drug combinations, now considered standard, are
cyclosporin (CsA) and methotrexate (MTX) or FK506 and
MTX [12].
Less consensus exists regarding the use of pretrans-
plant in vivo T-cell depletion. Some old studies as well as
recent studies suggest that T-cell antibodies administered
in vivo reduce GVHD [13-18], although large numbers of
UD transplantations have successfully been performed
without administration of T-cell antibodies [19-20]. In a
prospective randomized trial, we have recently shown that
antithymocyte globulin (ATG) administered pretransplant
can significantly reduce acute GVHD in patients undergo-
ing UD transplantation [21]. That trial also suggested that
chronic GVHD may be reduced in patients receiving ATG
pretransplant.
In the present study we focused on chronic GVHD in
160 consecutive patients, with a minimum follow-up of
1.5 years, who received (n = 102) or did not receive (n = 58)
in vivo T-cell depletion with ATG as part of their condition-
ing regimen. These patients all received grafts in our trans-
plant unit and were recipients of either UD transplants or
partially mismatched related-donor transplants.
MATERIALS AND METHODS
Patients
A total of 160 consecutive patients received an unmanipu-
lated allogeneic BMT from an alternative donor (unrelated or
related 1-2 antigen mismatched) at our unit between 1993
and 2000; the median year of transplantation was 1998.
Clinical details are outlined in Table 1 according to
whether patients were given or not given ATG pretransplan-
tation. Most patients had chronic myeloid leukemia (65 and
41 in the ATG and non-ATG groups, respectively), acute
leukemia (23 and 14), lymphoma (2 and 0), myelodysplasia
(10 and 1), or aplastic anemia (2 and 2). Patients were cared
for in single rooms with high-efficiency particulate air
(HEPA)-ﬁltered air from day –7 until at least day +30, when
they were discharged either to a conventional care unit or to
the outpatient clinic. All patients received high-dose
immunoglobulins (HDIgG) 400 mg/kg per week from day
–7 until day +100. In case of major ABO incompatibility, the
marrow was not depleted of red cells, but isohemagglutinins
were reduced in the patient to a titer of ≤1:16 in saline, with
1 or 2 plasma exchanges performed on days –2 and –1 before
BMT.
Donors and HLA Matching
The proportion of patients with 1 or more HLA-antigen
mismatch was 29% in the ATG group and 10% in the non-
ATG group (P = .005) (Table 1). Of the 127 UD transplants
selected by the Italian Bone Marrow Donor Registry
(IBMDR), 122 patients matched their donors for HLA-A and
-B according to serological analysis results and for DRB1
according to molecular biological analysis results, and 5
patients had 1-antigen mismatch. Of the related-donor trans-
plants, 2 were phenotypic matches (and were in the non-ATG
group), 3 had a single mismatch in either the GVH or HVG
vector, 18 had a 1-antigen mismatch in both vectors, and 10
had an additional 1-antigen mismatch in either the GVH or
the HVG vector.
Conditioning Regimen
The conditioning regimen consisted of cyclophos-
phamide (CY) (120 mg/kg) and TBI (9.9 or 12 Gy in frac-
tionated doses) in 95 patients [22] and CY (100-150 mg/kg)
with thiotepa (10-15 mg/kg) in 65 patients as previously
described [23]. There was more early-phase disease in
patients undergoing the CY-TBI regimen than in patients
undergoing the CY-thiotepa regimen (50% versus 27%, P =
.004), and more early-phase disease in patients younger than
35 years than in patients undergoing the CY-thiotepa regi-
men (67% versus 46%, P = .007). Because of this factor, sur-
vival outcome was measured separately.
Antithymocyte Globulin 
ATG (Thymoglobuline; Sangstat, Lyon, France) was
given in the conditioning regimen as a daily dose of
3.75 mg/kg on days –4 and –3 (total dose, 7.5 mg/kg) in
16 patients; on days –4, –3, and –2 (11.2 mg/kg) in 24 patients;
and on days –5, –4, –3, and –2 (15 mg/kg) in 62 patients.
Fifty-nine patients were given or not given ATG according
to the protocol of a prospective randomized trial; the
Table 1. Patient Clinical Data
ATG in the Conditioning Regimen
Yes No P
No. of patients 102 58
Patient age, median (range), y 34 (17-54) 29 (18-49) .0004
Donor age, median (range), y 36 (15-77) 37 (12-65) .2
Female donor + male recipient, n 27 14 .7
Donor type, unrelated/related mismatched, n 76/26 51/7 .04
HLA mismatched, n (%) 30 (29%) 6 (10%) .005
Diagnosis, chronic myeloid leukemia/other, n 65/37 41/17 .6
Diagnosis-to-BMT interval, median (range), d 896 (115-7935) 980 (197-3468) .6
Advanced phase (>1st complete remission/chronic phase), n (%) 62 (61%) 32 (55%) .6
Stem cell source, BM, n 102 58
Nucleated cells, median (range), ×108/kg 3.9 (1-12.6) 3.5 (1.5-9.2) .1
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remaining 101 patients were assigned to receive or not
receive ATG according to nonrandomized institutional pro-
tocols that were developed between 1993 and 2000.
Bone Marrow Harvest 
Bone marrow was harvested from unrelated donors under
general anesthesia in the respective donor centers and trans-
ferred via courier to our unit without further manipulation.
Bone marrow from related donors was harvested in our unit.
The median number of infused cells ×108/kg (available for all
patients) was comparable in the ATG and non-ATG groups
(3.5 and 3.1, respectively, P = .1) (Table 1), as was the number
of CD34 cells ×106/kg (4.7 and 4.4, P = .8, available in 22 and
27 patients in the ATG and non-ATG groups, respectively).
GVHD Prophylaxis
All patients received CsA 1 mg/kg as a continuous intra-
venous (IV) infusion from day –7 to day –2, then 2 mg/kg IV
from day –1 to day +20, and then 5 to 10 mg/kg per day
orally from day +21 until at least day +365. MTX was given
at the conventional dose of 15 mg/m2 on day +1 and
10 mg/m2 on days +3, +6, and +11.
Cytomegalovirus Prophylaxis and Treatment
All patients received foscarnet from day –7 to day +30 at
the dose of 30 mg/kg twice daily, then 90 mg/kg per day 5
days a week from day +31 to day +10. A different dose of fos-
carnet was used in the 8 patients who entered a dose-ﬁnding
study on foscarnet for cytomegalovirus (CMV) prophylaxis
[24]. Patients were monitored for CMV antigenemia once a
week from day +1 to day +30 then twice weekly until day
+100 as described elsewhere [25]. CMV antigenemia was
treated by increasing the dose of foscarnet to 180 mg/kg if
the number of CMV antigen–positive cells was 1/2 × 105 to
4/2 × 105 and with combined treatment with ganciclovir (5-10
mg/kg per day for 15 days) if the number of CMV
antigen–positive cells was greater than 4/2 × 105 [26].
Statistical Analysis
The chi-square test was used for 2 × 2 tables; the rank
sum and t tests were used for differences between continuous
variables; and the Kaplan Meier actuarial survival plots were
used for time-dependent analysis (survival, transplantation
mortality, and relapse) [27].
RESULTS
Acute GVHD
Acute GVHD was scored as 0-I, II, and III-IV in 49%,
37%, and 14% of patients receiving ATG and in 26%, 46%,
and 28% of patients not receiving ATG (P = .008) (Table 2).
Acute GVHD grade II-IV and grade III-IV were both
significantly reduced in ATG patients compared to non-
ATG patients: 51% versus 74%, P = .004; and 14% versus
28%, P = .03, respectively.
Chronic GVHD
Chronic GVHD was scored as absent, limited, or exten-
sive in patients surviving 100 days (n = 123, 77, and 46,
respectively, in the 2 groups). It was absent in 65% to 37% of
the ATG/non-ATG patients, limited in 27% to 48%, and
extensive in 8% to 15% (P = .01) (Table 2). Chronic GVHD
was also scored separately for ATG/non-ATG related mis-
matched transplant recipients (absent 13/3, limited 5/1,
extensive 0/2, P = .03) and ATG/non-ATG UD transplant
recipients (absent 37/14, limited 16/21, extensive 6/5, P =
.02). The risk of limited + extensive chronic GVHD was
lower in the ATG patients than in the non-ATG patients in
all age groups: <25 years (n = 27) (16% versus 66%, P =
.008), ≥25 years (n = 96) (38% versus 61%, P = .03),
≥35 years (n = 47) (37% versus 67%, P = .07), ≥45 years (n =
18) (33% versus 67%, P = .3), the P value being different
because there were fewer patients in the older age group.
We then analyzed the proportion of patients with chronic
GVHD (limited and extensive) at different time points. In the
ATG group there were signiﬁcantly fewer patients than in the
non-ATG group with chronic GVHD at 6 months (14% ver-
sus 30% P = .03), 1 year (7% versus 41% P = .0001), 2 years
(16% versus 36%, P = .02), and 4 years (5% versus 34%, P =
.002) and beyond 4 years (0% in 19 patients at risk versus 29%
in 24 patients at risk, P = .01) (Figure 1).
The risk of the extensive form of chronic GVHD was
significantly different in the ATG/non-ATG groups for
patients older than 35 years (8% versus 33%, P = .03) and less
so in younger patients (≤35 years) (7% versus 9%, P = .8).
Dose of ATG and GVHD 
There was a dose effect of ATG on acute and chronic
GVHD. Acute GVHD was scored as grade III-IV in 8%,
16%, and 31% of patients receiving 15 mg/kg, 7.5 mg/kg, or
3.75 mg/kg of ATG, respectively. A similar dose effect was
observed for chronic GVHD, which developed in 34%,
25%, and 50% of patients, respectively.
Performance Status 
We analyzed patient performance status as indicated by
Karnowski score. The proportion of patients in the ATG
group and in the non-ATG group with a Karnowski score
greater than 90 was 49% versus 36%, respectively, at
Table 2. Acute and Chronic GVHD and Patient Outcome
ATG in the
Conditioning Regimen
Yes No P
No. of patients 102 58
Acute GVHD
Grade 0-I 49% 26%
Grade II 37% 46%
Grade III-IV 14% 28% .008
Chronic GVHD
Absent 65% 37%
Limited 27% 48%
Extensive 8% 15% .01
Limited + extensive, n (%) 27 (35%) 29 (63%) .002
Causes of death, n
Leukemia 12 4
GVHD 15 12 
Infection 24 9 
Other treatment-related cause 6 3 .5
Alive, yes/no, n 45/57 30/28 .2
Follow-up, median (range), y 3.9 (1.5-6.4) 5.6 (1.7-8.9) .0001
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6 months (P = .1), 59% versus 50% at 1 year, 71% versus
70% at 2 years, 88% versus 72% at 4 years, and 93% versus
56% beyond 4 years (P = .01) (Figure 2). The number of
patients at risk at each time point is also outlined in Figure 2;
beyond 4 years there were 19 patients in the ATG group and
24 patients in the non-ATG group.
Immunosuppressive Therapy
We also evaluated the proportion of patients in whom oral
cyclosporin and oral prednisone were discontinued during the
same time intervals (Figure 3). The difference in the number of
patients off cyclosporin in the ATG group and in the non-ATG
group increased with time and became signiﬁcant at 2 years
(28% versus 3%, P = .003). The average daily dose of oral
cyclosporin was also signiﬁcantly lower in the ATG group than
in the non-ATG group: 71 mg versus 129 mg, respectively, at 1
year (P = .0005), 48 mg versus 77 mg at 2 years (P = .07), and
21 mg versus 55 mg (P = .02) at 4 years. Similarly, the propor-
tion of patients off prednisone at 2 years was also signiﬁcantly
greater for the ATG group than the non-ATG group (21%
versus 3% P = .01).
Immune Reconstitution 
Lymphocyte count recovery was slower in patients
receiving ATG than in patients not receiving ATG. On day
+30, absolute lymphocyte counts (×109/L) were 0.25 versus
0.46, P = .03. Thereafter (day +50, day +100, day +180) lym-
phocyte counts were comparable (0.54 versus 0.37, P = .1;
0.64 versus 0.56, P = .4; and 1.2 versus 1.01, P = .7). CD3
absolute counts (×109/L) were not signiﬁcantly different in
patients receiving or not receiving ATG at 100 days (0.18
versus 0.32, P = .6), day +180 (0.43 versus 0.79, P = .8) and
day +730 (1.6 versus 1.28, P = .7). The same was true for
CD4 counts.
Survival, Transplant Mortality, and Relapse
The outcome parameters survival, transplantation mor-
tality, and relapse were analyzed separately in patients receiv-
ing CY-TBI and CY-thiotepa because the latter regimen was
given mainly to older patients with advanced disease. In the
CY-TBI group, survival rates were 56% versus 59% (P = .7)
for ATG (n = 48) and non-ATG patients (n = 47), transplan-
tation mortality rates were 33% versus 34% (P = .9), and
relapse rates were 18% versus 17% (P = .8). In the CY-
thiotepa group survival rates were 33% versus 18% (P = .3)
for ATG (n = 54) and non-ATG patients (n = 11), transplan-
tation mortality rates were 46% versus 54% (P = .6), and
relapse rates were 37% versus 45% (P = .8).
Causes of Death
The causes of treatment failure are outlined in Table 2.
There were fewer deaths due to GVHD in the ATG group
than in the non-ATG group (15% versus 21%, P = .8 by the
Fisher exact test) and more deaths, but not significantly
more, due to infections in the ATG group than in the non-
ATG group (23% versus 15%, P = .1).
DISCUSSION
This study shows a significant difference in chronic
GVHD between patients receiving ATG and those not
receiving ATG before an alternative donor transplant. This
result was seen despite the fact that the ATG patients were
significantly older, by a median of 6 years, and had more
HLA-mismatched donors, almost one third compared to
10% for the non-ATG group. The reduction in chronic
GVHD was evident for patients receiving marrow from
unrelated donors, as well as for patients receiving a graft
from a partially HLA-mismatched family member, a result
that may be of interest because of the variability of HLA
mismatching in this setting: not only the number of mis-
matched antigens/alleles (known and unknown) but also the
relevance of different mismatches may confound the out-
come [28]. The present study suggests that the administra-
tion of ATG pretransplant to patients undergoing unrelated
or related mismatched allografts confers signiﬁcant protec-
tion against chronic GVHD, despite the inevitable large
variability of HLA matching.
We found that prophylactic ATG treatment was protec-
tive against chronic GVHD for patients of all ages, including
very young patients. Indeed, in the small group of patients
aged less than 25 years (27 patients), only 18% of the ATG
Figure 1. Proportion of patients with chronic GVHD (limited +
extensive) at various time points after transplant. The difference
between the ATG group and the non-ATG group increases with time
and is signiﬁcant at almost all time points.
Figure 2. Proportion of patients with a performance status
(Karnowski score) greater than 90: there are signiﬁcantly more patients
with a long-term normal performance status in the ATG group than in
the non-ATG group post-transplant.
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patients developed chronic GVHD compared to 68% of the
non-ATG patients. In all other age groups, with cut-offs at
25, 35, and 45 years, there was a stable average halving of
chronic GVHD rates from 60% for the non-ATG patients
to 30% for the ATG patients. The extensive form of chronic
GVHD seemed to be more of a problem in the older
patients (>35 years), in whom it could be significantly
reduced by using ATG, and less so in younger patients (≤35
years old).
Landmark analysis was performed to assess the evolu-
tion of chronic GVHD over time. This analysis was possi-
ble because we had been using a relational database for
more than 15 years, and patients admitted to the unit or
seen in the outpatient clinic were scored on the central
database at each examination. This system creates a multiple-
record follow-up and allows access to data on patient
symptoms and laboratory test results at any given time
posttransplant. The landmark analysis showed a difference
in chronic GVHD at each time point, and the difference
seemed to become greater with time: at the last follow-up,
more than 4 years posttransplant, there were 19 patients at
risk for GVHD in the ATG group, of whom none had lim-
ited or extensive chronic GVHD; of the 24 at-risk patients
in the non-ATG group, 29% had chronic GVHD (4 lim-
ited and 3 extensive). Therefore it seemed that at least
some patients who had developed chronic GVHD in the
ATG group had cleared their symptoms by the time of last
follow-up and were free of this complication. This result
was reflected in a better performance status in the ATG
patients: the percentage of patients with a Karnowski score
greater than 90 was higher in the ATG patient group than
in the non-ATG group, significantly so beyond 4 years
from transplantation. This finding is in keeping with the
known impact of chronic GVHD on quality of life [1].
Because there were more patients without chronic GVHD
in the ATG group, at 2 years posttransplantation more
patients in this group were no longer receiving immuno-
suppressive treatment with cyclosporine and prednisone.
Virtually every patient in the non-ATG group was still
receiving immunosuppressive therapy at 2 years posttrans-
plantation, whereas approximately one third of patients in
the ATG group were not receiving immunosuppressive
therapy.
Survival rates were analyzed separately in patients
receiving TBI- or thiotepa-containing regimens, because
the latter regimen was given mainly to older patients with
advanced disease. For ATG and non-ATG patients,
respectively, survival rates were 56% versus 59% in the
CY-TBI group and 33% versus 18% in the CY-thiotepa
group. Transplant mortality and relapse rates were also
comparable if not identical. Therefore the overall out-
come parameters of survival, transplant mortality, and
relapse were unaffected by ATG in the conditioning regi-
men, a result that may seem contradictory to what we
have said up until now. Indeed, if GVHD in its acute and
chronic forms is the major complication of UD marrow
transplantation, with considerable associated morbidity
and mortality, then preventing this complication should
ameliorate transplantation mortality and survival. So why
was this outcome not observed? In our first prospective
trial we showed that a reduction in acute GVHD was
accompanied by an increased risk of infections [21], prob-
ably due to impaired immune reconstitution, especially in
patients receiving high-dose ATG, a result also reported
by others [29]. This tells us that reducing acute GVHD
with ATG administered pretransplantation will not trans-
late into reduced early transplant mortality. What about
chronic GVHD? Again, we saw a reduction of GVHD but
no effect on survival. Here we can propose 2 explanations.
The first is that limited chronic GVHD may not increase
the risk of death because of its antitumor effect [30]. The
second is that extensive chronic GVHD may take many
years to show an effect on survival [8]. In keeping with
this hypothesis, the EBMT/ IBMTR (European Group
for Blood and Marrow Transplantation/International bone
Marrow Transplant Registry) have performed a second
analysis of marrow versus peripheral blood transplants.
Whereas no effect on survival was demonstrated in their
first analysis, despite an increased risk of chronic GVHD
[31], the second analysis, with an additional 4-year follow
up, showed a significantly increased transplant mortality
in patients with early disease who received peripheral
blood transplantations (N. Schmitz, personal communi-
cation). We could therefore be seeing the effect of pre-
transplant ATG on chronic GVHD but not yet on sur-
vival, because of time.
Therefore, evaluation of the effect of ATG on survival
may have to await additional follow-up, although we are
already seeing a positive effect on quality of life and time at
which immunosuppressive therapy can be discontinued.
In conclusion, this study suggests that patients receiving
ATG in the conditioning regimen have comparable survival
rates but a signiﬁcantly lower risk of chronic GVHD, better
performance status, and a higher chance of discontinuing
immunosuppression than do patients not receiving ATG.
These results may also be obtained in other treatment pro-
grams in which chronic GVHD is a problem, such as HLA-
matched peripheral blood transplantation [32], and may war-
rant a prospective randomized trial in that setting.
Figure 3. Proportion of patients who discontinued oral cyclosporin
treatments at different time points. More patients in the ATG group
than in the non-ATG group were off cyclosporin at all time intervals;
the difference was signiﬁcant at 2 years posttransplantation.
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